Bente Mertz Nørgård1,2, Jan Nielsen1,2, Torben Knudsen3,4, Rasmus Gaardskaer Nielsen5,6, Michael Due Larsen1,7, Line Riis Jølving1,2, Jens Kjeldsen8,9. 1. Center for Clinical Epidemiology, Odense University Hospital, Odense, Denmark. 2. Research Unit of Clinical Epidemiology, Department of Clinical Research, University of Southern Denmark, Odense, Denmark. 3. Department of Medicine, Hospital of Southwest Jutland, Esbjerg, Denmark. 4. Department of Regional Health Science, Center Southwest Jutland, University of Southern Denmark, Esbjerg, Denmark. 5. Hans Christian Andersen Children's Hospital, Odense University Hospital, Odense, Denmark. 6. Research Unit of Pediatrics, Department of Clinical Research, University of Southern Denmark, Odense, Denmark. 7. Department of Clinical and Molecular Medicine, Norwegian University of Science and Technology, Trondheim, Norway. 8. Department of Medical Gastroenterology S, Odense University Hospital, Odense, Denmark. 9. Research Unit of Medical Gastroenterology, Department of Clinical Research, University of Southern Denmark, Odense, Denmark.
Abstract
AIMS: In the Danish population, we examined whether patients treated with thiopurines, methotrexate, systemic corticosteroids, anti-tumour necrosis factor (TNF)-α agents, anti-interleukin therapeutic agents, selective immunosuppressive agents and cyclosporine/tacrolimus had an increased risk of hospitalization for COVID- 19, compared to the background population. METHODS: A nationwide cohort study including all people alive in Denmark on 1 March 2020. Exposed patients constituted those exposed to thiopurines (n = 5484), methotrexate (n = 17 977), systemic corticosteroids (n = 55 868), anti-TNF-α agents (n = 17 857), anti-interleukin therapeutic agents (n = 3744), selective immunosuppressive agents (n = 3026) and cyclosporine/tacrolimus (n = 1143) in a period of 12 months prior to 1 March 2020 (estimated time of outbreak in Denmark). We estimated the adjusted risk of hospitalization for COVID-19 for patients treated with the above-mentioned categories of medications, compared to the rest of the population. RESULTS: The adjusted odds ratios of hospitalization in patients treated with corticosteroids and cyclosporine/tacrolimus were 1.64 (95% confidence interval [CI] 1.35 to 2.00) and 4.75 (95% CI 1.96 to 11.49), respectively. The risks of hospitalization in patients treated with thiopurines, methotrexate, and anti-TNF-α agents, were 1.93 (95% CI 0.91 to 4.08), 0.74 (95% CI 0.43 to 1.28), 1.00 (95% CI 0.52 to 1.94), respectively. The number of outcomes in patients treated with anti-interleukin therapeutic agents and selective immunosuppressive agents was too small for analysis. CONCLUSION: Patients treated with systemic corticosteroids and cyclosporine/tacrolimus had a significantly increased risk of being hospitalized for COVID-19. Our study does not uncover whether the increased risk is related to the drug itself, the underlying condition for which the patient is treated or other factors.
AIMS: In the Danish population, we examined whether patients treated with thiopurines, methotrexate, systemic corticosteroids, anti-tumour necrosis factor (TNF)-α agents, anti-interleukin therapeutic agents, selective immunosuppressive agents and cyclosporine/tacrolimus had an increased risk of hospitalization for COVID- 19, compared to the background population. METHODS: A nationwide cohort study including all people alive in Denmark on 1 March 2020. Exposed patients constituted those exposed to thiopurines (n = 5484), methotrexate (n = 17 977), systemic corticosteroids (n = 55 868), anti-TNF-α agents (n = 17 857), anti-interleukin therapeutic agents (n = 3744), selective immunosuppressive agents (n = 3026) and cyclosporine/tacrolimus (n = 1143) in a period of 12 months prior to 1 March 2020 (estimated time of outbreak in Denmark). We estimated the adjusted risk of hospitalization for COVID-19 for patients treated with the above-mentioned categories of medications, compared to the rest of the population. RESULTS: The adjusted odds ratios of hospitalization in patients treated with corticosteroids and cyclosporine/tacrolimus were 1.64 (95% confidence interval [CI] 1.35 to 2.00) and 4.75 (95% CI 1.96 to 11.49), respectively. The risks of hospitalization in patients treated with thiopurines, methotrexate, and anti-TNF-α agents, were 1.93 (95% CI 0.91 to 4.08), 0.74 (95% CI 0.43 to 1.28), 1.00 (95% CI 0.52 to 1.94), respectively. The number of outcomes in patients treated with anti-interleukin therapeutic agents and selective immunosuppressive agents was too small for analysis. CONCLUSION:Patients treated with systemic corticosteroids and cyclosporine/tacrolimus had a significantly increased risk of being hospitalized for COVID-19. Our study does not uncover whether the increased risk is related to the drug itself, the underlying condition for which the patient is treated or other factors.
Authors: Meryl Waldman; Maria Jose Soler; Clara García-Carro; Liz Lightstone; Tabitha Turner-Stokes; Megan Griffith; Joan Torras; Laura Martinez Valenzuela; Oriol Bestard; Colin Geddes; Oliver Flossmann; Kelly L Budge; Chiara Cantarelli; Enrico Fiaccadori; Marco Delsante; Enrique Morales; Eduardo Gutierrez; Jose A Niño-Cruz; Armando J Martinez-Rueda; Giorgia Comai; Claudia Bini; Gaetano La Manna; Maria F Slon; Joaquin Manrique; Alejandro Avello; Raul Fernandez-Prado; Alberto Ortiz; Smaragdi Marinaki; Carmen Rita Martin Varas; Cristina Rabasco Ruiz; Milagros Sierra-Carpio; Rebeca García-Agudo; Gema Fernández Juárez; Alexander J Hamilton; Annette Bruchfeld; Constantina Chrysochou; Lilian Howard; Smeeta Sinha; Tim Leach; Irene Agraz Pamplona; Umberto Maggiore; Paolo Cravedi Journal: Kidney360 Date: 2021-12-03
Authors: Yuwei Sun; D Claire Miller; Idara Akpandak; Evan M Chen; Benjamin F Arnold; Nisha R Acharya Journal: Ophthalmology Date: 2022-05-17 Impact factor: 14.277